← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Arrowhead Research ARWR $8.28B	80	-17	-18%	$98.5M
27	BLCM 27 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	78	-3	-4%	$149M
28	NSTG 28 DELISTED NanoString Technologies, Inc. NSTG	77	+4	+5%	$245M
29	29 Atara Biotherapeutics ATRA $95.2M	71	-14	-16%	$377M
30	30 Invesco Biotechnology & Genome ETF PBE $431M	71	-15	-17%	$61.8M
31	SIOX 31 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	70	0	0%	$291M
32	32 Lineage Cell Therapeutics LCTX $243M	66	-2	-3%	$99.9M
33	ATHX 33 DELISTED Athersys, Inc. Common Stock ATHX	64	+15	+31%	$21.9M
34	34 Regenxbio RGNX $465M	64	-2	-3%	$180M
35	35 Rocket Pharmaceuticals RCKT $256M	58	-2	-3%	$142M
36	36 uniQure QURE $1.51B	57	-7	-11%	$109M
37	37 Veracyte VCYT $3.64B	55	-9	-14%	$82.9M
38	38 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	50	-2	-4%	$13.3M
39	39 Arbutus Biopharma ABUS $850M	49	-2	-4%	$73.1M
40	ADAP 40 DELISTED Adaptimmune Therapeutics ADAP	49	0	0%	$260M
41	41 Editas Medicine EDIT $369M	49	+49	–	$625M
42	42 Vericel Corp VCEL $2.11B	49	+9	+23%	$76.7M
43	43 Fate Therapeutics FATE $231M	46	-8	-15%	$28.4M
44	44 Abeona Therapeutics ABEO $268M	45	0	0%	$19.5M
45	45 Cellectis CLLS $110M	44	-4	-8%	$178M
46	46 Fortress Biotech FBIO $64.4M	44	+4	+10%	$19.7M
47	47 Voyager Therapeutics VYGR $126M	43	+8	+23%	$87M
48	NVTA 48 DELISTED Invitae Corporation NVTA	41	-7	-15%	$216M
49	49 Opus Genetics IRD $333M	36	+2	+6%	$7.45M
50	50 Pluri PLUR $12.1M	36	-1	-3%	$12.3M